Xgeva 120 mg Injection

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Product photography not yet supplied — this space will show official packaging imagery once provided by the business.

Product Overview

Xgeva 120 mg Injection contains denosumab, a monoclonal antibody that binds RANKL, a protein involved in bone breakdown. The source listing describes it as used in bone conditions to strengthen bone and reduce the risk of fractures, given by a healthcare professional at set intervals.

Active ingredient
Denosumab
Strength
120 mg
Dosage form
Solution for injection
Therapeutic class
RANKL inhibitor (monoclonal antibody)
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with denosumab and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • The source listing describes use in bone conditions to strengthen bone and reduce fracture risk
  • Described as used in patients considered at high risk of fractures
  • Exact approved indication and strength should be confirmed with the prescriber and against local labelling
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Given as a subcutaneous injection by a doctor or nurse, at the interval set by the prescriber
  • The full course should be completed as directed
  • Calcium and vitamin D supplementation may be advised by the prescriber

Described Side Effects

Commonly described side effects include:

  • Bone, muscle, or joint pain
  • Rash
  • Headache and back pain
  • Constipation and abdominal discomfort
  • Hair loss

Any severe, persistent, or unexpected reaction requires prompt medical attention.

Precautions

  • An up-to-date medical and dental history should be shared with the healthcare team
  • Pregnancy or breastfeeding should be discussed with the prescriber
  • Adequate calcium and vitamin D intake may be required during treatment
  • Any persistent side effects should be reviewed by a clinician

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

It contains denosumab, a RANKL inhibitor. The source listing describes use in bone conditions to reduce fracture risk; the exact approved indication should be confirmed against local prescribing information. SDO Pharma has not independently verified these claims.

As a subcutaneous injection administered by a doctor or nurse at the interval set by the prescriber.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services